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Abstract
Background: Exposure to contemporary seasonal influenza A viruses affords partial immunity to pandemic H1N1 2009
influenza A virus (pH1N1) infection. The impact of antibodies to the neuraminidase (NA) of seasonal influenza A viruses to
cross-immunity against pH1N1 infection is unknown.
Methods and Results: Antibodies to the NA of different seasonal H1N1 influenza strains were tested for cross-reactivity
against A/California/04/09 (pH1N1). A panel of reverse genetic (rg) recombinant viruses was generated containing 7 genes
of the H1N1 influenza strain A/Puerto Rico/08/34 (PR8) and the NA gene of either the pandemic H1N1 2009 strain (pH1N1)
or one of the following contemporary seasonal H1N1 strains: A/Solomon/03/06 (rg Solomon) or A/Brisbane/59/07 (rg
Brisbane). Convalescent sera collected from mice infected with recombinant viruses were measured for cross-reactive
antibodies to pH1N1 via Hemagglutinin Inhibition (HI) or Enzyme-Linked Immunosorbent Assay (ELISA). The ectodomain of
a recombinant NA protein from the pH1N1 strain (pNA-ecto) was expressed, purified and used in ELISA to measure cross-
reactive antibodies. Analysis of sera from elderly humans immunized with trivalent split-inactivated influenza (TIV) seasonal
vaccines prior to 2009 revealed considerable cross-reactivity to pNA-ecto. High titers of cross-reactive antibodies were
detected in mice inoculated with either rg Solomon or rg Brisbane. Convalescent sera from mice inoculated with
recombinant viruses were used to immunize naı ¨ve recipient Balb/c mice by passive transfer prior to challenge with pH1N1.
Mice receiving rg California sera were better protected than animals receiving rg Solomon or rg Brisbane sera.
Conclusions: The NA of contemporary seasonal H1N1 influenza strains induces a cross-reactive antibody response to pH1N1
that correlates with reduced lethality from pH1N1 challenge, albeit less efficiently than anti-pH1N1 NA antibodies. These
findings demonstrate that seasonal NA antibodies contribute to but are not sufficient for cross-reactive immunity to pH1N1.
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Introduction
The development of an influenza vaccine that confers broad-
spectrum immunity is of paramount importance in the fight
against future or re-emerging influenza pandemics. In an effort to
discover this vaccine panacea, a myriad of formulations have been
developed and pre-clinically tested with varied results [1–7]. The
continuous antigenic drift of circulating viruses poses a serious
challenge towards achieving cross-protection against divergent
influenza strains [8,9]. The influenza vaccine formulations are
updated every year to protect against various influenza strains.
This severely limits the immunity to future (re-)emerging influenza
viruses. Although licensed influenza vaccines are restricted to
inducing primarily homotypic protection, studies indicate that
natural exposure to seasonal H1N1 influenza A strains induce
cross-reactive serum antibodies to the antigenically distinct
pandemic H1N1 2009 influenza A virus (pH1N1) [10,11].
The presence of serum neutralizing antibody responses to the
hemagglutinin (HA) protein is a well-established hallmark correlate
of protection against influenza infection. Exposure from previous
infections or immunization with influenza vaccines from either the
1976 or contemporary 2006–2009 seasons induce cross-reactive
neutralizing antibodies to the HA of pH1N1 (pHA) in elderly
recipients [10,12,13]. The implication is that these neutralizing
antibodies may to some degree provide protection against pH1N1
in certain populations. Interestingly, serological analysis of animals
previously exposed to contemporary seasonal influenza A/
Brisbane/59/07 H1N1 strain show little or no seroconversion to
pH1N1 when measured by either hemagglutination inhibition (HI)
or microneutralization (MN) based methods [4,14]. In spite of
limited or lack of detectable cross-reactive neutralizing antibodies,
prior infection with seasonal strains partially reduces weight loss,
virus replication and transmission of pH1N1 in mouse, ferret,
guinea pig or porcine challenge models [4,14–16] or limits
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with contemporary seasonal strains do the severity of infection and
level of virus replication greatly decrease after pH1N1 challenge
[16]. Taken together, these studies illustrate that repeated exposures
to seasonal influenza viruses throughout the life span of humans
may be beneficial in not preventing but rather limiting pH1N1-
related morbidity. The mere fact that cross-reactive neutralizing
antibodies against pHA were not detected in previous studies [4,14–
16] and due to the highly variable nature of HA antigenicity
warrants investigation into whether another viral moiety of seasonal
influenza strains contributes to this cross-protective response.
Several studies point to the importance of the second most
abundant surface influenza glycoprotein neuraminidase (NA) in
conferring cross-reactive immunity [1,18,19]. Case in point, anti-N2
serum antibodies provide protection against antigenically distinct
viruses belonging to the same subtype [19]. Also, anti-N1 (H1N1)
partially protects mice against H5N1 challenge [18]. The importance
of NA in providing immunity against pH1N1 has not yet been
defined. Nonetheless, we along with others previously showed that
seasonal influenza viruses from 2004–09 seasons possess the capacity
to boost cross-reactive serum antibodies to the NA of pH1N1 mainly
in elderly individuals [20,21]. Therefore, it is probable that seasonal
NA proteins, which belong to a different genetic lineage than pH1N1
NA protein, can provide cross-protective immune responses.
Little is known regarding the role of cross-reactive antibodies
raised against the NA of antigenically distinct seasonal influenza
strains [20] on the protective response to pH1N1. Our aim in this
report is to evaluate the magnitude of the cross-reactive immune
response to the NA of pH1N1 after exposure to the NA of
contemporary seasonal H1N1 influenza viruses. Also, do these
antibodies to antigenically distinct NA proteins add to immunity
against pH1N1? In the context of an influenza infection, we
assessed the contributing role of anti-NA antibodies on immunity
to pH1N1 using recombinant viruses encoding only one gene (NA)
belonging to contemporary seasonal H1N1strains or less recent
H3N2. Because ELISA are more sensitive than neuraminidase
inhibition assays [22] for detecting NA-specific serum antibodies
[23], we used this method in our studies. By ELISA, we show that
a single infection with recombinant viruses with a seasonal N1 but
not N2 NA gene stimulate high levels of cross-reactive serum
antibodies to baculovirus-expressed pNA-ecto from the A/
California/04/09 (pH1N1) strain. Furthermore, N1 not N2 NA
antibodies contribute partial protection against lethality from wild-
type pH1N1 infection. As predicted, a recombinant virus encoding
the NA of pH1N1 afforded the greatest degree of immunity
against pH1N1 challenge. The results presented here highlight the
notion that in addition to HA, the NA component of seasonal
influenza vaccines should be optimized in future preparations.
Methods
Ethics statement
All experimental procedures conducted in mice were reviewed
and approved by St. Jude Children’s Research Hospital (SJCRH)
Institutional Animal Care and Use Committee, approval number
428. All human study protocols were approved by the University
of British Columbia and the Institutional Review Board of the
University of Connecticut Health Center. The approval numbers
for all human studies are H06-00231, H06-03969, H07-02008,
H08-01775, and 03-340.
Mice
Six-eight week old wild-type (wt) Balb/c or Severe combined
immunodeficient, (SCID) mice lacking T and B lymphocytes on
the Balb/c background were obtained from Jackson laboratories
(Bar Harbor, Maine). All mice were housed in the Animal
Resource Center SPF Bio-safety level 2 or 2+ facility at SJCRH.
Virus propagation
The reverse genetic (rg) 7+1 recombinant viruses with 7 genes
from A/Puerto Rico/08/34 (PR8) and the NA gene segment from
either A/Solomon/03/06 (rg Solomon), A/Brisbane/59/07 (rg
Brisbane), A/California/04/09 (rg California) H1N1 viruses or
the A/Aichi/02/68 (rg X231) H3N2 strain were generated using
the 8-plasmid reverse genetic method [24]. The wt H1N1 human
influenza viruses, A/New Jersey/11/76 (wt New Jersey), A/
Solomon Islands/03/06 (wt Solomon), A/Brisbane/59/2007 (wt
Brisbane) or pandemic: A/Tennessee/1-560/2009 (wt Tennessee),
A/California/04/09 (wt California) were all obtained from the
World Health Organization influenza collaborating laboratories.
The recombinant and wt viruses were propagated in the allantoic
cavities of 10-day old embryonic chicken eggs. The infection titers
of all viruses were determined by using the Reed and Muench
method [25], and expressed as the log10 of the 50% infectious dose
(EID50) of fluid.
Virus sequencing
To confirm that the recombinant viruses did not acquire
mutations after virus rescue, RNA was isolated from each virus
using the RNeasy minikit (Qiagen, Valencia, CA). RT-PCR was
performed using universal NA primers [24]. Sequencing reactions
were performed and analyzed using the Lasergene sequencing
analysis software (DNASTAR). Only the seasonal H1N1 rg
Solomon virus acquired one single amino acid substitution at
position 469 changing from threonine to alanine. This substitution
lies outside of the major antigenic (immunogenic) regions of NA
[26].
Neuraminidase protein production
Purified NA protein from pH1N1 was prepared as described
previously [26,27]. Synthetic, codon-optimized cDNA encoding
an N-terminal 66His-tag, a 15-residue tetramerization sequence,
a thrombin cleavage site, and NA residues 83–468 (in N2
numbering) of the A/California/04/2009 H1N1 influenza virus
were cloned into the pAcGP67B plasmid (BD Biosciences,
Franklin Lakes, NJ). These residues consisted of the NA
ectodomain excluding the cytoplasmic and trans-membrane
domains. The ectodomain of NA rather than the full-length
protein was synthesized due to the presence of antibody/antigenic
sites located on the ectodomain region which also is the only
region exposed on the surface of the virion. A baculovirus
expression system (Invitrogen, Life Technologies, Carlsbad, CA)
was used to express recombinant NA protein ectodomains in Sf9
insect cells. The pNA-ecto protein secreted into the cell culture
medium was recovered by metal affinity chromatography using a
HisTrap column (GE Healthcare Life Sciences). The pNA-ecto
was further purified by size-exclusion chromatography on a
Superdex200 16/60 column (GE Healthcare) in 20 mM sodium
phosphate pH 8.0 and 150 mM Na Cl. Purified tetrameric pNA-
ecto was concentrated to 0.6 mg/ml.
Immunization of mice
Balb/c mice (n=20 per group) were inoculated intranasally
with either phosphate-buffered saline (PBS) or 10
3 EID50 of rg
Solomon, rg Brisbane, or rg California viruses. Because rg X231
virus is lethal when administered at a dose of 10
3 EID50 mice were
infected at a dose of 10
2 EID50.To mimic multiple exposures in
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3
EID50 of either wt New Jersey, wt Brisbane, wt Solomon or wt
Tennessee wild-type viruses. Three weeks later, mice were boosted
with 10
3 EID50 of wt Solomon or PBS (mice primed with
Tennessee). All viruses were diluted in a final volume of 30 mlo f
PBS. Mice were infected after sedation with isoflurane.
Sera collection
Sera were collected from each Balb/c mouse via the retro-
orbital method three weeks after prime and boost with wt viruses
or inoculation with recombinant viruses. In separate studies, SCID
mice were bled 1, 4, 7 and 10 days post sera transfer (n=16 per
sera group). Sera samples were collected from each treatment
group, heat inactivated for 30 minutes at 56uC and tested for
virus-specific antibodies prior to use in passive transfer studies. We
received human sera from a prospective study of adults 65–93
years old (median, 74 years), recruited in the Greater Vancouver
Area of British Columbia, Canada or in the vicinity of the Greater
Hartford Area of Connecticut during the 2007–08 and 2008–09
influenza seasons. A written informed consent was obtained from
all participants in the study. All participants received the standard
dose of the licensed trivalent split-inactivated (TIV) seasonal
influenza vaccine containing A/Solomon Islands/03/2006-like
(H1N1), A/Wisconsin/67/2005-like (H3N2), and B/Malaysia/
2506/2004-like viruses in 2007–2008 or A/Brisbane/59/2007
(H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and B/Florida/
04/2006-like viruses in 2008–2009 season. Sera were collected
from each participant 4 weeks after vaccination.
Passive transfer of serum antibodies and virus challenge
To assess the cross-protective efficacy of serum antibodies to the
NA of seasonal strains, a volume of 100–150 ml of pooled heat
inactivated sera collected three weeks after inoculation with
recombinant or wt viruses were passively transferred intraperito-
neally into naı ¨ve recipient Balb/c or SCID mice (n=5210 per
treatment group). Because each pooled sera could not be
normalized to a standard titer of NA antibody without non-
specifically diluting HA antibodies, undiluted sera with equivalent
HI titers to PR8 (1,280–2,560) were used in each passive transfer
study. Recipient animals were intranasally challenged 18–
24 hours later with 30 mlo f1 0
6 EID50 wt California. Animals
were monitored daily for mortality and weight loss up to 12 days
post-infection (dpi).
Serum analysis
For HI assays, sera were treated with receptor destroying
enzyme (Denka Seiken Co., Ltd., Tokyo, Japan) overnight then
tested for HI titers [28] against wt Solomon, wt Brisbane, wt
Tennessee, wt California or rg Solomon, rg Brisbane, or rg
California. Samples without detectable HI titers were assigned a
titer of,40. Antigen-specific Ig (IgA, IgG, and IgM) antibodies in
either mouse or human sera were measured by ELISA. Briefly, 96-
well microtiter plates (Corning, Lowell, MA) were coated over
night at 4uC with purified pNA-ecto. After blocking with 3% dry
milk in 16PBS20.05% Tween220 at 37uC, serial dilutions of
sera were incubated at room temperature for 1 hour. Antibodies
were detected using goat-anti mouse or anti-human Ig conjugated
to alkaline phosphatase (Rockland, Immunochemicals Gilberts-
ville, PA) and p-nitrophenyl phosphate as the substrate (KPL Inc.,
Gaithersburg, MD). The absorbance for each well was measured
at 405 nm using a microplate reader (Bio-Rad, Los Angeles, CA).
Endpoint antibody titers were defined as the reciprocal of highest
sera dilution resulting in an absorbance of >0.150. Cytokines were
measured in sera collected from mice infected with recombinant
viruses. The picogram per milliliter (pg/ml) concentration of 32
mouse cytokines was determined using the multiplex bead system
according to the manufacturer instructions (Millipore Corpora-
tion, Billercia, MA). Multiplex beads were measured using the
Millipore Luminex 200 instrument (Luminex Corporation, Austin,
TX) and quantified with the Luminex6Ponent version 3.1
instrumentation software (Luminex Corporation).
Neuraminidase activity of recombinant viruses or purified
pNA-ecto protein
Comparisons of the NA activity in each recombinant virus prep
or purified pNA-ecto was tested by using a miniaturized format of
the neuraminidase assay [22]. Briefly, using a 96-well polypropyl-
ene PCR plate (RPI, Mount Prospect, IL), serial dilutions of either
virus diluted in PBS or pNA-ecto diluted in PBS (containing 1–
10 mM CaCl2 for optimal activity) was incubated with the
substrate fetuin (25 mg/ml) overnight at 37uC. The NA activity of
each virus preparation or pNA-ecto was determining by
calculating the percent increase in the cleavage of fetuin (Optical
Density: 550 nm) when compared to PBS only wells.
Titrations of virus in lungs
Lungs from Balb/c mice were harvested at 5 dpi (n=5 per
treatment group) immediately after mice were euthanized with
Avertin (2, 2, 2-tribromoethanol; Sigma Aldrich, St. Louis. MO).
Tissue samples were homogenized and processed as described
[28]. The titer of virus in each sample was calculated by the Reed
and Muench method [25] and expressed as 50% tissue culture
infective dose (TCID50).
Statistical analysis and amino acid sequence alignment
For statistical analysis, significant differences in Kaplan-Meier
survival curves were determined by using the log rank test (Graph
Pad Prism version 5.03). The database GenBank was used to
obtain NA amino acid sequences of seasonal (Solomon and
Brisbane) and pandemic (Tennessee and California) influenza
strains. Because several C-termini residues of both Solomon and
Tennessee were not available in GeneBank at the time of the
analysis, we retrieved sequences of only the ectodomain for each
virus strain. To determine the percent homology between each
seasonal and pandemic ectodomain sequences, a clustalW amino
acid sequence alignment was performed as described previously
[29] (BioEdit Sequence alignment editor version 7.0.9 for,
Windows 95/98/NT). Significant differences in the Ig ELISA
titers were determined by student’s t-test (Excel for Windows XP).
Differences in NA activity from recombinant viruses or differences
in virus titers in the lung were calculated by the analysis of
variance method (ANOVA) followed by post hoc comparison tests
(Graph Pad Prism).
Results
Seasonal and pandemic 2009 H1N1 influenza strains
share high sequence homology in their neuraminidase
protein
Despite the genetic divergence between seasonal influenza
viruses versus the recently emerged pH1N1, they share several
conserved epitopes [30,31]. To determine the overall similarity
between the NA of these viruses, a sequence alignment at the
amino-acid level was performed comparing the NA ectodomain
sequence of influenza H1N1viruses. The ectodomain NA of
seasonal: Solomon, Brisbane or pandemic: Tennessee viruses were
all compared to the NA of pH1N1 California virus. Identical
Role of Neuraminidase Antibodies on Cross-Immunity
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pandemic strain Tennessee shares the highest identity (99%) with
California (Fig. 1B). Contemporary seasonal strains Solomon and
Brisbane also share identity to California (84%). These data
indicates high percent identity exists within the region containing
all of the antigenic epitopes. This supports the idea that antibodies
raised against seasonal NA as a result of previous infections or
vaccination may cross-react with the NA of pH1N1.
Characterization of purified NA ectodomain protein from
the A/California/04/09 influenza strain
We generated recombinant NA ectodomain from the pH1N1
California strain (pNA-ecto) using a baculovirus insect cell
expression system. The purified pNA-ecto was subjected to size
exclusion chromatography and found to elute as a single peak at
,200 kDa, consistent with pNA-ecto forming tetramers (Fig.
S1A). The purity of recombinant pNA-ecto was confirmed using
denaturing Coomassie blue-staining analysis (Fig. S1B). These
data suggest that the pNA-ecto protein is correctly-folded in a
native tetrameric form as found on the surface of influenza virions.
Our previous report demonstrates that immunization with TIV
boosted the level of cross-reactive serum antibodies to whole-
inactivated wt pH1N1 in elderly humans [20]. In the current
report, we tested the activity and immunogenicity of purified pNA-
ecto. First we tested NA activity using a miniaturized format of the
NA assay [22]. Compared to PBS only wells, purified pNA-ecto
displayed increased activity only in the presence of calcium
chloride [(CaCl2) (Fig. S2A)]. Next we used an ELISA-based
approach to measure the reactivity between pNA-ecto and sera
collected from elderly humans immunized with TIV containing
either Solomon or Brisbane H1N1 influenza components. We
observed a large cross-reactive response to pNA-ecto after
immunization with TIV containing either seasonal H1N1
component (Fig. S2B). There was no significant difference in titer
between vaccinees (P>0.27). As predicted, there was no reactivity
in pooled sera collected from Balb/c mice inoculated with PBS but
a high degree of recognition by pooled convalescent sera from
mice infected with wt California (positive control sera, Table 1). In
separate studies, convalescent sera from DBA/2 mice infected with
the unrelated H3N2 influenza strain, A/Shorebird/Delaware/79/
Figure 1. Alignment of amino acid sequences of the neuraminidase from seasonal or pandemic H1N1 influenza viruses. The GenBank
sequences of the NA of Solomon, Brisbane, Tennessee and California were aligned using the clustalW alignment program (BioEdit software, Windows
95/98/NT). Numbers to the left of each line indicates amino acid position. Gaps in the alignment are represented as dashed lines. A) Sequences that
are shaded in grey indicate identical amino acids between the full length NA of H1N1 viruses. The black arrow indicates the starting sequences of the
ectodomain for each virus strain (residue 82 to end).* assumption that the NA sequence of Solomon has identical residues at C-terminus. B) The
percent identity of the NA ectodomain between Solomon, Brisbane, Tennessee viruses compared to California was calculated using BioEdit.
doi:10.1371/journal.pone.0026335.g001
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shown), thus demonstrating the specificity of the response to pNA-
ecto. These results indicate that the antigenicity, specificity and
presumably the structural conformity of pNA-ecto were retained
relative to the native form.
The neuraminidase of seasonal influenza viruses
stimulate cross-reactive antibodies to purified pNA-
ectodomain protein in mice
To address whether exposure to seasonal influenza strains could
elicit cross-reactive antibodies to the NA of pH1N1, we generated
several 7+1 rg viruses encoding the NA gene of Solomon,
Brisbane, or California with 7 remaining PR8 genes. Because the
only gene in these recombinant viruses that differed was the NA,
we tested the NA activity of all viruses. Each virus preparation was
serially diluted two fold and tested for NA activity by the
miniaturized format of the NA assay as previously mentioned
[20,22]. Significant differences in mean activity (cleavage of fetuin
substrate) were seen between recombinant viruses (Fig. 2)
(*P=0.007). The overall activity of wt California was higher than
that of rg Solomon (@P,0.05) but not rg Brisbane (P.0.05).
Several wt seasonal influenza viruses induce cross-reactive
serum antibodies to HA or NA of pH1N1 [10,11,20]. To establish
whether the NA of seasonal H1N1 strains can stimulate cross-
reactive antibodies to pH1N1 NA, Balb/c mice were infected with
an equivalent dose (10
3 EID50) of a single recombinant virus (rg
Solomon, rg Brisbane, rg California). All groups were compared to
mice inoculated with PBS or wt California as a negative or positive
control, respectively. As predicted, each recombinant virus
induced high and similar neutralizing serum antibody titers (HI)
to the HA of PR8 (homologous) in mice (Table 1), suggesting that
each virus stimulated an overall immune response of equivalent
magnitude. In agreement with previous observations [14–16,32],
no HI titers were detected (,40) to the HA of wt California in
animals infected with seasonal recombinant viruses. As predicted,
sera collected from mice infected with the unrelated rg
X231(H3N2 A/Aichi/02/68) displayed similar HI titers to PR8
and no reactivity to the HA of wt California (Table 1). We next
assessed cross-reactive antibodies using purified pNA-ecto by
ELISA. Infection with rg Brisbane or rg Solomon induced 16–32-
fold less pNA-ecto titers (320–640) than compared to rg California
(10,240) as measured by ELISA. Nevertheless, pNA-ecto titers in
animals infected with rg Solomon or rg Brisbane were markedly
higher than titers in PBS-inoculated (40) or rg X231 infected mice
(80). As expected, no pH1N1-specific HI titers were detected in
animals receiving PBS alone (,40) (Table 1). These results
demonstrate that the antibodies to the NA of contemporary
seasonal H1N1 strains have cross- reactivity to the NA of
California.
Antibodies to the neuraminidase of seasonal H1N1
viruses associate with immunity to pH1N1
Mice immunized with DNA encoding the NA of the seasonal
H1N1 strain, A/New Caledonia/20/99 were found to have
reduced weight loss and enhanced survival upon lethal H5N1
challenge [18], demonstrating a role for NA in heterologous
immunity. Because sera from mice inoculated with rg Solomon, rg
Brisbane or rg California displayed alike HI titers but a 16–32 fold
difference in anti-pNA-ecto antibody titers when compared to rg
California sera (Table 1), we hypothesized that this would
correlate with a reduction in immunity to pH1N1.To address
this, sera from animals previously inoculated with recombinant
viruses or either PBS (negative control) or wt California (positive
control) were passively transferred into Balb/c mice. Recipient
animals were then challenged with a lethal dose of wt California.
Mice receiving rg California sera displayed increased survival
when compared to animals receiving sera from negative control
mice (P,0.001) (Fig. 3A). Also, rg Solomon or rg Brisbane sera
protected better than that of PBS sera (P(0.02). Interestingly,
transfer with rg California sera or positive control sera resulted in
an equivalent percentage of survival in mice (70%) (P=0.03).
However, positive control sera provided the best protection from
weight loss compared to all sera tested (Fig. 3B). Sera collected
Table 1. Serum antibody titers in Balb/c mice after priming
with reverse genetic 7+1 NA recombinant viruses as
determined by hemagglutination inhibition and ELISA assays.
GROUP
a HI HI ELISA (Ig)
b
7+1 rg viruses
c
Homologous
HA
d California HA
e California NA
f
NA Solomon 1,280 ,40 640
NA Brisbane 2,560 ,40 320
NA California 1,280 ,40 10,240
NA X231 2,560 ,40 80
PBS
g ,40 ,40 40
Positive Control
h ,40 640 102,400
aEach group of mice primed intranasally with 7+1 recombinant viruses.
bELISA titers expressed as reciprocal of the highest dilution of pooled sera with
an O.D. value of>0.150 when tested against purified NA ectodomain of A/
California/04/09.
cRecombinant viruses with 7 gene segments from PR8 and the NA segment
from the indicated H1N1 or H3N2 influenza A strain.
dPooled sera tested for HI titers against rg PR8.
ePooled sera tested for HI titers against wild-type A/California/04/09.
fPooled sera tested for Ig titers against purified NA ectodomain of A/California/
04/09.
gMice primed with PBS alone.
hPooled convalescent sera from Balb/c mice infected with wild-type A/
California/04/09.
doi:10.1371/journal.pone.0026335.t001
Figure 2. Enzymatic analysis of the NA activity between
recombinant viruses. A panel of 7+1 rg recombinant viruses was
generated by reverse genetics. Each recombinant virus contained the 7
gene segments from the PR8 strain and the NA gene from Solomon,
Brisbane, or California. Using a 96-well plate, the activity of each NA in
serial two fold dilutions of virus was determined by calculating the
percent increase in cleavage of the substrate fetuin between each virus
and PBS only wells. Activity was measured at an O.D. of 550 nm.
Significant differences in mean activity were seen between rg viruses
(*P=0.007). The overall activity of wt California was higher than that of
rg Solomon (@P,0.05) but not rg Brisbane (P.0.05). Data is
representative of three independent experiments.
doi:10.1371/journal.pone.0026335.g002
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survival to that of PBS sera (10%) (Fig. S3A). Mice transferred with
either rg X231 or PBS sera loss weight at similar kinetics for up to
6 dpi with the exception of one single mouse that recovered in
each group (Fig. S3B). The low percent protection induced by rg
X231 sera was associated with minimal antibody reactivity to
pNA (Table 1). Therefore, the N1 of contemporary seasonal
influenza strains contributed greater cross-immunity than that of
an unrelated older N2 strain. These data indicate that NA
antibodies derived from different seasonal H1N1 strains afford
alike cross-immunity against lethal pH1N1 infection. Also, the titer
of cross-reactive antibodies to pNA-ecto associates with partial
protection against lethality.
We then determined if cross-reactive NA antibodies were
associated with a reduction in virus replication. Expectedly, virus
titers in PBS recipient mice were greater than that of titers in mice
receiving rg California sera at 5 dpi (P,0.05) (Fig. 3C). Although
positive control sera protected 70% of mice from lethality,
surprisingly, this sera did not significantly reduce virus replication
in the lung when compared with PBS sera (P.0.05). No difference
was observed between either rg Solomon or rg Brisbane and PBS
sera (P.0.05). Because NA serum antibodies increased survival
from lethal challenge, we tested how long passively acquired
antibodies persisted in the blood stream several days post transfer.
To test this, rg California sera were passively transferred into
antibody-deficient SCID animals prior to wt pH1N1 challenge
and pNA-ecto-specific antibodies were measured 1, 4, 7 and 10
days post transfer (Fig. 3D). Considerably high titers of antibodies
were observed out to at least 10 dpi in SCID mice that received rg
California sera. The persistence of these antibodies however did
not diminish virus replication in the lung of any SCID animal
when compared to PBS-inoculated SCID mice (P>0.45) (data not
shown) demonstrating that these passively-acquired antibodies
were not sufficient for virus clearance.
Multiple exposures to wild-type seasonal viruses provide
cross-reactive immune responses to the neuraminidase
of pandemic influenza virus
Humans are likely to be exposed to different strains of seasonal
influenza viruses throughout their lifetime. In ferrets, the
Figure 3. The effect of N1NA antibodies on immunity to pandemic H1N1 2009 challenge. Naı ¨ve Balb/c mice were injected intraperitoneally
with pooled convalescent sera collected from mice infected with 7+1 rg recombinant viruses. Control mice were injected with either sera from mice
inoculated with PBS or wt California. All passivelytransferred mice were challengedwith a lethaldose (10
6 EID50) of wt pH1N1 virus. Survival, weightloss
and virus titers were monitored post challenge. A) Percent survival was measured between animals daily for 12 days post virus challenge; differences
between rg California and PBS: P,0.001. Comparison between rg Solomon or rg Brisbane to PBS: P,0.02. B) Average weight loss in each treated group
after virus challenge was monitored daily for 12 days. C) Virus titers in the lungs of all challenged mice at 5 dpi assessed by TCID50. The persistence of
passively transferred antibodies in the blood stream was assessed using antibody-deficient SCID mice. Titers of cross-reactive antibodies to pNA-ecto
were determined by ELISA. D) Differences in total Ig (IgM, IgA, IgG) titers were measured in the serum of SCID mice at 1 (P=0.03), 4 (P=0.03), 7 (P=0.10)
and 10 (P=0.02) days post passive transfer with rg California. Data is representative of two independent experiments.
doi:10.1371/journal.pone.0026335.g003
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if animals are infected twice with wt seasonal influenza viruses
[16]. It has been shown previously that the immune response to
NA is impaired by previous exposure to related HA [33,34]. To
determine whether multiple exposures to contemporary wt
seasonal strains can contribute to cross-reactive antibodies to the
NA of pH1N1, Balb/c mice were primed with wt Solomon or wt
Brisbane then three weeks later boosted with wt Solomon. As
expected, priming with wt Solomon induced high HI titers post
prime (1,280) and boost (1,280) against homologous virus (Table 2).
The absence of increased homologous titers post boost suggested
that these mice were at least marginally protected from secondary
homologous infection. Mice that were primed with wt Brisbane
displayed an eight fold less HI titer (160) to wt Solomon than
homologous boost. As seen in previous studies [14–16,32], we
could not detect HI titers to wt California after exposure to
contemporary seasonal influenza strains. Expectedly, we saw a
considerably high level of response to the pNA-ecto of wt
California in mice primed with wt Tennessee (1,440–4,022).
There was equivalent cross-reactive pNA-ecto titers post boost in
mice primed with wt Brisbane (320) or wt Solomon (320).
However, boosting with wt Solomon reproducibly increased the
cross-reactive titers to pNA-ecto in mice primed with either wt
Solomon or wt Brisbane (160 to 320). In separate studies, priming
with swine-origin H1N1 A/New Jersey/11/76 (wt New Jersey)
enhanced the cross-reactive pNA-ecto titers after boost with wt
Solomon (1280) (data not shown). This is in agreement with the
observation that previous exposure to wt New Jersey boosts pre-
existing cross-reactive antibodies to pH1N1 in elderly humans
[10]. These individuals likely underwent natural infection with
contemporary seasonal viruses. As predicted, animals inoculated
with only the wt Tennessee developed a strong reactivity to pNA-
ecto (102,400–204,800). Therefore, our results strongly mirror the
scenario of multiple exposures in nature and suggest that cross-
reactive pNA-ecto titers induced by repeated exposure to seasonal
influenza strains may contribute to reducing the severity of pH1N1
infection.
Discussion
The goal of the current study was to define two parameters: [i]
The extent of cross reactivity of antibodies raised against the NA of
antigenically distinct [10,12,31] seasonal H1N1 influenza strains
to the NA of pH1N1 and [ii] The contribution of these cross-
reactive antibodies on the outcome of severe wt pH1N1 infection.
Here we show that exposure to the NA of contemporary H1N1
seasonal strains induce antibodies with high reactivity to pNA-
ecto. Furthermore, these antibodies associate with immunity albeit
marginally against pH1N1-related lethality. Using wt seasonal
viruses, we also show that multiple exposures with these wt strains
resulted in reactivity to pNA-ecto. These studies demonstrate that
the HA is not the sole immune correlate in protection from a
severe pH1N1infection, but in addition to HA, the NA of seasonal
influenza plays a contributing role in inducing cross reactive-
immune responses to antigenically variant strains. The magnitude
of cross-reactive HA antibodies in response to pH1N1 has been
described elsewhere [10]. Several limitations exist when protective
responses are determined by antibody responses to HA alone.
Measuring exclusively HA antibodies may severely underestimate
the degree of immunity by omitting the detection of antibodies
raised against other viral proteins [35]. In our previous study [20],
we discovered that antibodies to NA did not positively correlate
with antibodies to HA, thus supporting this idea.
We cannot rule out that inadequate protection mediated by
seasonal NA antibodies was due to the differences in NA content,
NA activity of recombinant viruses, antigenic inhibition by PR8
HA or slight differences in virus replication between the
recombinant viruses. The generation of purified pNA-ecto
provided a useful tool to also address antigenicity by an ELISA-
based approach. In theory, the NA content of rg California viruses
may be addressed using the homologous pNA-ecto protein,
however, a method to calculate the precise concentration of NA
in each virus preparation is currently lacking. Regrettably, our
inability to normalize the NA concentration in each recombinant
virus tested presented a limitation in our studies. However, mice
infected with these recombinant viruses responded with equivalent
HI titers to homologous (PR8) and heterologous (pHA) proteins.
Novel approaches of determining NA concentrations in virus
preparations are necessary to begin to address the effect of NA
content on antibody-based protection. Nevertheless, some data
suggest that the NA activity of influenza vaccine preparations may
be used as a marker for NA content and standardization [21].
Previously, it has been show that the activity of NA is correlated
with the magnitude of the antibody response to this protein
[21,36,37]. In our current studies, we observed a marked
difference in NA activity between rg Solomon versus rg California.
We do not believe that the cross-reactive antibody response to
pNA-ecto was affected by NA activity. This is supported by the
observation that infection with a rg PR8 virus containing the NA
of PR8 induced 4–8 fold less cross-reactive antibodies in mice but
retained significantly higher NA activity than that of rg Solomon
(P,0.05) and rg Brisbane (P,0.05) NA proteins (data not shown).
It is unlikely that insufficient antibody-mediated immunity to
pH1N1 was partially due to antigenic competition by PR8 HA
because we previously demonstrated that the HA of PR8 does not
alter recognition to or activity of NA [20]. Although not directly
tested in our studies, the kinetics of virus replication between the rg
Table 2. Serum antibody titers in Balb/c mice after prime or
boost with wild-type viruses as determined by
hemagglutination inhibition and ELISA assays.
GROUP
a HI HI ELISA (Ig)
b
Solomon/
Solomon Solomon HA
c California HA
d California NA
e
Post Prime 1,280 ,40 160
Post Boost 1,280 ,40 320
Brisbane/
Solomon
Post Prime ,40 ,40 160
Post Boost 160 ,40 320
Tennessee/ PBS
f
Post Prime ,40 1,440 204,800
Post Boost ,40 4,022 102,400
aEach group of mice primed (0 dpi) and boosted (21 dpi) intranasally with wild-
type H1N1 influenza viruses.
bELISA titers expressed as reciprocal of the highest dilution of pooled sera with
an O.D. value of>0.150 when tested against purified NA ectodomain of A/
California/04/09.
cPooled sera collected three weeks post prime or boost and tested for HI titers
against wild-type A/Solomon/03/06.
dPooled sera collected three weeks post prime or boost and tested for HI titers
against wild-type A/California/04/09.
ePooled sera tested for Ig titers against purified NA ectodomain of A/California/
04/09.
fMice primed with A/Tennessee/1-560/09 and boosted with PBS alone.
doi:10.1371/journal.pone.0026335.t002
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mice. Assuming this to be true, the fact that all passively
transferred sera were normalized in their HI titer, yet varied in
the level of anti-pNA-ecto antibodies support our hypothesis that
NA antibodies contributed to cross-immunity.
Because of the presence of other virus proteins (e.g, NP, HA), we
acknowledge that in our current studies, the full degree of
immunity mediated by anti-NA antibodies was not established.
Since we utilized live viruses in our studies rather than single NA
constructs, we could not preclude a contributing role for various
PR8 proteins. We concede that the presence of non NA proteins of
PR8 may have added to immunity against pH1N1. In our report,
the NA was presented in the context of an influenza infection and
therefore studied as an indirect measure of the role NA in
immunity to pH1N1. The HI titers (homologous and heterolo-
gous) in sera induced by the recombinant viruses were alike, while
anti-pNA-ecto antibodies varied, suggesting that NA antibodies
contribute to protection. This was confirmed in a separate
preliminary study where convalescent sera from wt pH1N1
infection was absorbed to pNA-ecto and therefore, partially
depleted of NA antibodies. The partially-depleted sera afforded
less protection (than non-depleted sera) from pH1N1 challenge
when passively transferred into naı ¨ve Balb/c mice (data not
shown). We conclude that antibodies to NA contributed but were
not the sole antibody that afforded immunity against pH1N1
challenge.
We used live viruses to mirror the scenario of multiple infections
where humans develop varying levels of cross-reactive responses
throughout lifetime, which is largely dependent on the number of
exposures. With repeated exposures, humans are presumably
more equipped immunologically to deal with pH1N1 infection.
Our findings using wt seasonal strains are in agreement with
previous results that demonstrate repeated infections or vaccina-
tion with seasonal strains [16,38] is capable of inducing cross-
reactive responses to pH1N1. It has been shown that the immune
response to NA is impaired by competition by previous exposure
to closely-associated HA [39,40]. It was unlikely that responses to
NA were inhibited by previous exposure to homologous HA in our
studies using wt Solomon since we observed an increase in anti-
pNA-ecto titer after boost. Our results support previous studies
using DNA or purified NA constructs, which show a contributing
role for anti-NA antibodies in protection against heterologous
virus challenge [1,18,41].
The mechanism by which cross-reactive antibodies to seasonal
NA may contribute to protection against pH1N1 is unknown.
However, the well-established role for NA antibodies is to provide
a reduction in virus replication [42,43], or cross-linking of virus
particles on infected cells [44] or enhancing complement-mediated
pathways [45] which can all likely diminish disease severity
[19,46]. In our studies however, we saw a trend of reduced virus
replication in the lungs using sera from mice transferred with rg
California or positive control antibodies. However, the difference
reached statistical significance only when rg California, not
positive control sera were administered. We cannot account for
this unexpected result. This may be due to the high lethal dose of
the virus used to challenge mice. Future studies are necessary to
determine whether sera can diminish virus replication using sub-
lethal doses of pH1N1. Despite the lack of reduction of virus
replication using serum antibodies induced by seasonal recombi-
nant viruses, we found that mice passively transferred seasonal
NA-specific antibodies survived lethal pH1N1infection longer than
mice transferred naı ¨ve sera (PBS). This suggests that a reduction of
virus replication is not the sole mechanism of anti-NA antibody-
mediated immunity in our model. Studies to identify the method
employed by these cross-reactive serum antibodies are required to
address the mechanism of cross-immunity.
It is more likely that cross-immunity generated by exposure to
seasonal H1N1 influenza strains require the coordinated efforts of
not merely HA and NA antibodies but also cross-reactive memory
T lymphocytes responses [47–49]. This is supported by the
observation that in our studies, SCID mice lacking B and T
lymphocytes developed uncontrolled virus replication in the lungs
after transfer with rg sera (data not shown). The substantial
conservation of several non-NA major histo-compatibility com-
plex-1 epitopes between seasonal influenza strains and that of
pH1N1 support a role for T lymphocytes in cross-reactive
immunity [30]. Studies in mice where two inoculations with wt
Solomon or wt Brisbane and in separate studies, wt New Jersey
(data not shown), show a strong cross-reactive antibody response
to pNA-ecto which was likely accompanied by substantial cross-
reactive CD4
+ and CD8
+ T lymphocyte responses. An important
function of cross-reactive T lymphocytes is the secretion of
cytokines [47,50]. Cytokines play an important role in protection
against influenza viruses [51–53]. We saw a 9.6 fold increase in
only IL-15 in rg X231 versus PBS sera (data not shown).
However, it is unlikely that the presence of this cytokine impacted
immunity upon adoptive transfer, because rg-X–31 sera afforded
merely 10% survival from challenge. These results demonstrate
that the partial immunity observed after passive transfer was due
to the presence of antibody.
Our results are in agreement with findings that reveal an
important role for exposure to seasonal H1N1 influenza viruses via
natural infection or vaccination in the generation of cross-reactive
immune responses to pH1N1 [4,10,11,16,17,48,49,54,55]. How-
ever, we address for the first time the contributing role of serum
N1 NA antibodies in the cross-protection against pH1N1-related
severity. Our results mirror findings that show N2 fail to confer
cross-immunity against the genetically distinct H1N1 subtype [19].
In light of our recent findings, we propose that in addition to the
HA protein, the NA content must be measured and optimized in
future influenza vaccine formulations. Furthermore, our findings
agree with the observation that in some cases, antibodies to HA
are not always a surrogate marker for immunity [36]. A report
indicated that the supplementation of NA from seasonal strains
into conventional seasonal vaccines may help to broaden the
immune response [56]. Therefore, the immune response to the
NA protein will be an important factor to consider in the planning
for future pandemics or the possible re-emergence of a more
virulent pH1N1 strain.
Supporting Information
Figure S1 Analysis of recombinant NA protein of
pandemic H1N1 2009 virus. The NA ectodomain protein of
the A/California/04/09 strain (pNA-ecto) was expressed using a
baculovirus insect cell expression system and purified (materials
and methods). A) Size-exclusion chromatography of recombinant
NA protein. Purified pNA-ecto protein elutes as a well-folded
tetramer (labeled black peak) with an apparent molecular size
of,200 kDa compared to molecular size standards (labeled gray
peaks) on a Superdex 200 size-exclusion chromatography column.
B) Denaturing Coomassie-stained gel of purified tetrameric pNA-
ecto (*) compared to molecular weight standards (kDa).
(TIF)
Figure S2 Activity and specific reactivity of purified
pNA-ecto protein. The activity of serial two-fold dilutions of
purified pNA-ecto in the presence or absence of CaCl2 was tested.
A) Activity was determined by calculating the percent increase in
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wells. Activity was measured at O.D. of 550 nm. B) ELISA were
performed using sera collected from humans (65–93 yrs old) 4
weeks post immunization with TIV containing either Solomon or
Brisbane H1N1 components. Pooled sera from mice inoculated
with PBS or infected wt California were used as negative, positive
controls respectively. Purified pNA-ecto was used to test the
specific reactivity of human and animal sera in all assays.
Individuals immunized with either TIV Solomon or Brisbane
H1N1 developed a large degree of cross-reactive Ig antibodies to
pNA-ecto by ELISA. Little reactivity was observed in negative
control sera. Conversely, high levels of Ig titers were seen in mice
infected with homologous wt virus. Observed differences in Ig
titers detected between Solomon and Brisbane human sera
(P>0.27). Data is representative of two independent experiments.
(TIF)
Figure S3 Analysis of anti N2 antibodies on protection
against pandemic H1N1 2009 virus. Naı ¨ve Balb/c mice were
injected intraperitoneally with pooled sera collected from mice
infected with 7+1r gX 231 or inoculated with PBS. All passively
transferred mice were challenged with a lethal dose (10
6 EID50)o f
wt pH1N1 virus. Survival and weight loss were monitored post
challenge. A) Percent survival was measured between animals
daily for 12 days post virus challenge. B) Average weight loss in
each treated group after virus challenge was monitored daily for
12 days. Data is representative of two independent experiments.
(TIF)
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